Myeloma News and Research

RSS

Novel magnetic therapy complements chemotherapy to enhance breast cancer treatment outcomes

Breast cancer is the leading cause of cancer-associated death for women worldwide. While chemotherapy is the mainstream treatment for breast cancer, more than 50% of women undergoing chemotherapy will experience at least one chemotherapy-related adverse side effect.

3 May 2022

Black and Hispanic people get the same benefits from CAR-T therapy as white patients

CAR-T therapy, a form of immunotherapy that revs up T-cells to recognize and destroy cancer cells, has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and most recently, multiple myeloma.

28 Apr 2022

Roswell Park experts to share latest advances in the treatment of blood-related cancers

Roswell Park Comprehensive Cancer Center specialists will share the latest advances and developments in the treatment of blood-related cancers at the 2022 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah, from April 23 to 26.

26 Apr 2022

A kind of kiss between cells plays key role in the fight between immune system and blood cancer cells

Researchers at The Ottawa Hospital and the University of Ottawa have discovered that a kind of kiss between cells, called trogocytosis, plays a key role in the battle between the immune system and blood cancer cells.

13 Apr 2022

Cancer risk and related mortality significantly higher among patients with kidney disease

Patients with kidney disease may have an increased risk of cancer and may be more likely to die from cancer.

8 Apr 2022

Study captures the immune effect of COVID-19 vaccine in patients with multiple myeloma

Most immunocompromised people with a blood cancer called multiple myeloma benefited from a third dose of COVID-19 vaccines, a promising sign after it was shown that two doses tended to not be sufficient for them.

6 Apr 2022

Study reveals how zinc supports immunity, suggests ways it could be used to improve health

Zinc's immune-boosting properties are well-established, but scientists haven't known exactly how it works.

1 Apr 2022

Trial reveals effectiveness of axi-cel as first-line treatment for high-risk lymphoma

Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma (LBCL).

21 Mar 2022

How effective is mRNA vaccination in multiple myeloma patients?

In a new study, researchers have been investigating the protection offered by the SARS-CoV-2 vaccine in patients suffering from multiple myeloma.

2 Mar 2022

Effect of mRNA-based COVID-19 vaccination in multiple myeloma patients

In a new study, researchers evaluated the immune responses induced by the mRNA-based SARS-CoV-2 vaccination against SARS-CoV-2 variants in multiple myeloma patients.

1 Mar 2022

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Multiple myeloma (MM) is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, investigators from Japan have recently found that a common component of amino acid transporters, CD98 heavy chain, represents an effective monoclonal antibody target in treating MM.

22 Feb 2022

Novel, rapid and efficient assay for SARS-CoV-2 neutralizing antibodies

Researchers validate a quick, highly efficient, and automated assay to detect neutralizing antibodies against SARS-CoV-2.

7 Feb 2022

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

2 Feb 2022

MD Anderson and Yingli Pharma announce strategic alliance to advance many oncology programs

The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.

20 Jan 2022

Metabolic vulnerabilities in malignant cells may lead to new breast cancer therapies

Metabolic differences could explain why some metastatic breast cancer cells rapidly generate tumors after migrating from primary tumors to the brain, while others linger for months or years before forming these secondary tumors, UT Southwestern scientists report in a new study.

12 Jan 2022

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Scientists recently demonstrated the efficacy of COVID-19 convalescent plasma therapy in improving the survival rate among patients with B-cell lymphoid malignancy and COVID-19.

5 Jan 2022

$Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma$

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second line therapy extended the length of time patients lived before their disease worsened (progression-free survival) compared with patients who received pomalidomide and dexamethasone.

21 Dec 2021

Study provides a more effective treatment approach to preventing graft-versus-host-disease

A new study led by UC Davis Health researchers showed that blocking IL-6 and TNF cytokines provides a more effective approach to preventing life-threatening graft-versus-host-disease (GVHD), an inflammatory condition that develops in patients after their allogeneic hematopoietic stem cell transplantation (allo-HSCT).

16 Dec 2021

Gene key to excessive cell proliferation could be a potential target for fatal pulmonary hypertension

A gene that is overexpressed in some aggressive cancers also appears to be key to the excessive cell proliferation that thickens the walls of pulmonary arteries and ultimately causes the right ventricle of the heart to fail, scientists report.